Pfizer hemophilia therapy hits goal in final-stage study
Fidanacogene elaparvovec was just as effective or superior to standard replacement of clotting factor in preventing annual bleeding events from hemophilia B.
By Madison Muller, Bloomberg
Pfizer’s gene therapy for a hemophilia B hit its main goal in a final-stage trial, moving closer to becoming a competitor to a similar one-time treatment that costs $3.5 million.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
